slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 25,351-25,380
Pages 1,437
Rows per page 30
Arc
25,351-25,380 of 43,093
16
The slide uses a table to compare patient demographics and clinical characteristics across different cancer types, specifically focusing on the sufficiency of the melanoma cohort for further development.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
17
Slide compares two generations of therapy; includes clinical metrics like cORR and mDOR.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a process-flow diagram to distinguish between two generations of TCR-T therapies and their respective trial phases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
19
The table highlights key clinical metrics including ORR, cORR, mDOR, and mFU for various patient subgroups.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
20
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Data cut-off Sep 30, 2023. N=16 patients.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
22
Data cut-off Sep 30, 2023. Includes extensive footnotes regarding methodology and specific patient cases.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
23
Includes waterfall plot for BOR and spider plot for response over time. Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
24
The slide uses a matrix structure to define the patient population and market opportunity.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
25
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
26
The slide uses a biological diagram to illustrate the synergy between CD4 and CD8 T cells in inducing tumor cell death.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses two line charts to demonstrate the superior durability of CD4 T cells in a serial killing assay.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
28
Includes specific clinical details on Grade 3/4 events for two patients in the highest dose cohort (DL4b).Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
29
Data cut-off Sep 30, 2023. Slide 29.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
30
Includes waterfall plot and spider plot (longitudinal response). Data cut-off Sep 30, 2023.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
31
Includes p-values for statistical significance across four distinct clinical metrics.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
32
Immatics | Investor Presentation Deck | 75 slidesImmatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide uses a two-row layout to contrast GEN1 and GEN2 therapies, each with a 'Next Step' callout.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Traction1 hit
68
The slide uses a grid layout with headshots and professional titles for 9 executives.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
69
The slide highlights the trans-atlantic nature of the organization with specific operational focus areas per site.Immatics | Investor Presentation Deck | 75 slides · Immatics
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a cause-and-effect structure to map platform capabilities to strategic outcomes.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
06
Uses a human anatomy diagram to map therapeutic areas to diseases; includes a pyramid at the bottom highlighting 'Other diseases' and the key differentiator 'Overcoming neurotoxicity'.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
08
The slide uses a structural diagram to highlight the specific modifications (COBRA Binder) that differentiate NXC-201 from the reference therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a diagram to map specific protein domains to their functional benefits.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
18
The chart demonstrates the mechanism of action: rapid cell expansion followed by clearance within 30 days, correlating with disease marker reduction.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
19
The slide uses a causal chain framework to link cellular pathology to systemic organ damage.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
20
The slide uses a grouped bar chart format to compare clinical outcomes across different therapeutic agents.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
21
The slide uses a table to contrast treatment efficacy and patient growth across disease stages.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Traction1 hit
23
Includes FDA approval precedents as a footnote to justify the clinical strategy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Pitch deck Investor relations Beat · Roadmap1 hit